Quetiapine for tamoxifen-induced insomnia in women with breast cancer

Psychosomatics

Volumn 50, Issue 2, 2009, Pages 159-161

  Pasquini, Massimo ^a   Speca, Azzurra ^a   Biondi, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; MIRTAZAPINE; PROMETHAZINE; QUETIAPINE; TAMOXIFEN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; DEPRESSION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERANCE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MOOD CHANGE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 66749092411     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.50.2.159     Document Type: Letter

References (15)

1. Lee KC, Ray GT, Hunkeler EM, et al: Tamoxifen treatment and new-onset depression in breast cancer patients. Psychosomatics 2007; 48:205-210
2. Land SR, Wickerham DL, Costantino JP, et al: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR), P-2. JAMA 2006; 21,295:742-751
3. Mourits MJ, Bockermann I, de Vries EG, et al: Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002; 20:1546-1550
4. Amin Z, Canly T, Epperson CN: Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev 2005; 4:45-58
5. Landry M, Di Paolo T: Effect of chronic estradiol, tamoxifen, or raloxifene treatment on serotonin HT receptor 1A. Mol Brain Res 2003; 112:82-89
6. 1A agonist, in normal volunteers Psychopharmacology 1994; 116:433-436
7. Cyr M, Ghribi o, Thibault C, et al: ovarian steroids and selective estrogen-receptor modulators: activity on rat brain NMDA and AMPA receptors. Brain Res Rev 2001; 37:153-161
8. Maenpaa H, Saransaari P, Tahti H: Kinetics of inhibition of glutamate uptake by antioestrogens. Pharmacol Toxicol 2003; 93:174-181
9. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-I, CV) [Italian version by Mazzi F, Morosini P, de Girolamo G, et al.]. Florence, Italy, Organizzazioni Speciali, 2000
10. Beck AT, Ward C: Reliability of psychiatric diagnoses: a study of clinical judgments and ratings. Am J Psychiatry 1962; 19:351-356
11. Bech P, Allerup P, Gram LF, et al: The Hamilton Depression Scale: evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981; 63:290-299
12. Morin CM, Espie CA: Insonnia: Guida alla valutazione e all'intervento psicologico. Milano, Italy, McGraw-Hill, 2004
13. Cohrs S, Rodenbeck A, Guan Z, et al: Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 2004; 174:421-429
14. Aghajanian GK, Marek GJ: Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 2000; 31:302-312
15. Tarazi FI, Baldessarini RJ, Kula NS, et al: Long-term effect of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003; 306:145-1151